What Ци-Клим Аланин Treats: Main Uses and Benefits

The primary therapeutic use of this preparation is to provide supportive relief from symptoms related to systemic imbalance and symptoms associated with acute or episodic changes during the climacteric period. This domain covers the unpredictable episodes of hot flashes, associated flushing, and excessive sweating that are characteristic of menopausal syndrome. The medication is relevant for easing symptoms related to physical discomfort and symptoms that interfere with daily functioning. This type of non-hormonal symptomatic support is commonly used by women who seek management for moderate to severe VMS, particularly when they cannot or choose not to use traditional Hormone Replacement Therapy (HRT), which is a common context for treatments addressing hot flashes and their impact on quality of life.

By easing the symptoms associated with the thermal episodes, it provides supportive relief during these episodes, which may assist with maintaining functional stability and comfort during symptomatic phases. It is often applied during phases when symptoms become more noticeable and may lead to temporary discomfort. This symptomatic support contributes to improved comfort during periods of heightened symptoms: “It helps patients cope more steadily with symptom fluctuations.” This treatment is considered relevant for easing the overall burden of persistent thermal discomfort in postmenopausal women.

Quick Fact	Relief for Symptom
Primary Use	Vasomotor Symptoms (VMS)
Symptom Type	Recurrent Hot Flashes and Flushing
Benefit	Supports Functional Stability and Comfort

The eligibility for using Ци-Клим Аланин (beta-Alanine) is strictly defined by regulatory documents, establishing clear restrictions and absolute contraindications. The medicine is intended solely for the adult female population experiencing vasomotor symptoms associated with the climacteric period.

Official Eligibility Exclusions

The medicine is subject to several formal prohibitions and limitations based on patient status, as defined in regulatory labeling:

Status	Population/Condition
Contraindicated	Patients with known hypersensitivity to beta-Alanine or any component.
Contraindicated	Individuals younger than 18 years of age.
Contraindicated	Women during pregnancy or lactation (breastfeeding).
Restricted	Patients with severe renal impairment (as stated in some official labeling).

The official eligibility profile confirms that use is absolutely prohibited when any of the contraindications are present. The safety and efficacy of the medicine have not been established in the pediatric population, leading to the formal age restriction. Therefore, eligibility requires that the patient is an adult woman in the climacteric period and does not meet any documented exclusion criteria.

The regulatory interaction profile for Ци-Клим Аланин, an anti-climacteric agent containing beta-Alanine, is characterized by the absence of formally documented drug-drug interaction data within major international government prescribing information. Unlike many conventional pharmaceutical products, official regulatory texts do not cite specific metabolic, transporter-based, or pharmacodynamic interactions that typically necessitate co-administration restrictions. The regulatory records are devoid of documented requirements for dose separation or warnings regarding alterations in drug exposure (AUC or Cmax) when combined with other medicines. Consequently, no formal listings of contraindicated combinations or mandatory timing separation rules are mandated in the official documentation.

The beta-Alanine regulatory status, which often classifies it as an amino acid derivative or supplement, contributes to this structure. The product’s official interaction profile is thus structured by the non-inclusion of these specific data points.

---

Official Interaction Status Summary

Interaction Category	Regulatory Status
Formal Contraindications	None formally documented.
Metabolic (CYP) / Transporter Interactions	None formally documented.
Timing / Food Restrictions	None formally documented.

---

This structure signifies that no documented restrictions are required based on the Cytochrome P450 enzyme system, major drug transport proteins, or risks of additive pharmacological effects.

Mechanism of Action: beta-alanine

Modulation of Peripheral Neurotransmitter Signaling

The mechanism of action centers on the active ingredient, beta-alanine (beta-alanine), acting as a weak competitive antagonist at specific peripheral GABA receptors (gamma-aminobutyric acid receptors). By temporarily binding to these receptor sites, beta-alanine modulates inhibitory neurotransmission in peripheral tissues, which are involved in the regulation of vascular tone. This action modifies early molecular steps that shape downstream systemic physiological outcomes.

---

️ Influence on Vascular Tone and Cutaneous Blood Flow

This action directly impacts the neurovascular unit, influencing the autonomic signals that regulate the diameter of blood vessels in the skin. The temporary disruption of peripheral inhibitory GABAergic signals results in localized peripheral vasodilation (widening of blood vessels). This leads to an observable increase in cutaneous blood flow and a measurable rise in skin temperature. This mechanistic domain operates in pathways that influence physiological regulation of vascular responses.

The administration of Ци-Клим Аланин is governed by standardized instructions detailing the route, dosage, and duration patterns derived from regulatory documents. The preparation, containing 400 mg of beta-alanine per tablet, is strictly intended for oral administration.

The regimen for adult use establishes a starting and maintenance dose of one to two tablets daily (corresponding to 400 mg to 800 mg). The official guidelines permit the total daily dose to be adjusted, if necessary, up to a maximum of three tablets daily (1200 mg). The medication is administered once per day or in divided doses and may be consumed without reference to mealtimes, allowing flexibility in the patient's daily schedule.

Administration Component	Official Instruction
Route of Administration	Oral
Standard Adult Dose	1 to 2 tablets daily
Maximum Daily Dose	3 tablets daily
Timing Relative to Food	Independent of mealtimes

The use of this medicine is restricted to the adult population, as it is not indicated for use in individuals under 18 years of age. Treatment is typically initiated for a course of five to ten days, continuing until the vasomotor symptoms subside. Since it is indicated that no habituation is observed, the treatment course may be prolonged without time restriction throughout the entire duration of the patient's symptoms. Recurrence of symptoms necessitates the commencement of a further cycle of administration, following the same initial dosing principles.

Recent Clinical Evidence: beta-Alanine (Active Ingredient)

Ци-Клим Аланин is a preparation based on the amino acid beta-alanine. Research has primarily investigated beta-alanine's use in managing vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, associated with the menopausal period. The objective of this research is to evaluate the reported effects on symptom frequency and intensity.

---

Study Findings on Vasomotor Symptoms

Clinical trials have examined whether beta-alanine supplementation could be associated with changes in the frequency and severity of VMS. In one study involving women with natural or surgical menopause, participants receiving beta-alanine reported an observable change in the number of daily hot flashes.

• Observed Symptom Changes: Study findings indicated that a percentage of women reported an improvement or a complete absence of hot flashes following a course of treatment with beta-alanine, in contrast to baseline symptom reporting. The reported effects were noted to increase over a 3-month period in some analyses.

• Quality of Life Metrics: Research has also explored the relationship between beta-alanine use and secondary outcomes, including sleep disturbances and overall quality of life during menopause.

---

Comparative and Safety Analysis

Trial analyses have compared adverse event reports for beta-alanine against placebo and other common treatments. beta-alanine is generally recognized as having a low acute and chronic toxicity profile based on available toxicological data. The most common reported side effect, often linked to higher doses, is transient paresthesia (tingling sensation).

• Mechanism of Action: While the precise mechanism related to VMS is still under investigation, beta-alanine is understood to potentially counteract the sudden release of histamine and may interact with cerebral neurotransmitter receptors involved in the body's temperature regulation process.

Common questions about Ци-Клим Аланин (FAQ)

Q: How quickly should I expect to see an effect from Ци-Клим Аланин?

A: The official administration guidelines outline a typical course of five to ten days until symptoms subside. Clinical trial summaries indicate that reported effects, such as changes in the frequency of hot flashes, may continue to increase over a period of up to three months of consistent use.

Q: Is it only for hot flashes, or does it help with other menopause symptoms?

A: According to the official product information, this medicine is indicated specifically for the symptomatic relief of vasomotor symptoms, such as hot flashes and flushing. However, research exploring the use of the active ingredient has also examined secondary health outcomes like sleep disturbances and overall quality of life during menopause.

Q: Are there any common digestive side effects reported for Ци-Клим Аланин?

A: Regulatory summaries primarily list nervous system disorders (like transient tingling) and vascular disorders (like flushing) as the common side effects. Digestive issues are not typically documented among the frequently reported adverse reactions in official summaries.

Q: Can I take Ци-Клим Аланин if I am also taking vitamins?

A: Official prescribing information notes the absence of formally documented requirements for dose separation or restrictions when combining this medicine with other products. Regulatory records do not mandate specific warnings regarding combined use with general vitamins or supplements.

Q: How is this different from generic beta-alanine?

A: Ци-Клим Аланин is formally classified by health authorities as an anti-climacteric agent (ATC G02CX), meaning it is regulated as a pharmaceutical product for a specific indication. While its active ingredient is beta-alanine, a naturally occurring amino acid, the specific product formulation is regulated under this classification.

Q: What happens if I stop taking Ци-Клим Аланин suddenly?

A: Regulatory documents indicate that no habituation is observed with the use of this medicine. If vasomotor symptoms return after stopping treatment, the official guidelines describe the allowance for a further cycle of administration to be re-initiated following the initial dosing principles.

Q: Why do some people experience a tingling sensation after taking it?

A: A transient tingling sensation (known as paresthesia) is a common, documented side effect of this medicine's active ingredient. The mechanism of action involves the modulation of peripheral neurotransmission, which is believed to be related to this temporary sensory effect.

Q: Does Ци-Клим Аланин affect sleep quality?

A: The medicine is primarily indicated for vasomotor symptoms which can disrupt sleep. While it is not indicated as a sleep aid, clinical research has explored the relationship between its use and secondary outcomes such as disturbances in sleep quality.

Q: Are there any studies comparing Ци-Клим Аланин to a placebo?

A: Clinical trial findings indicate that analyses have compared adverse event reports for the active ingredient (beta-alanine) against placebo. Research has also been conducted to evaluate the effects on symptom frequency and severity relative to a control group.

Q: Is Ци-Клим Аланин considered a natural remedy?

A: The active component is beta-alanine, which is a naturally occurring non-essential amino acid derivative. However, health authorities formally classify the product itself as an anti-climacteric agent (ATC G02CX) for its indicated use.

Q: What is the experience of other women who have used Ци-Клим Аланин?

A: Clinical trial findings documented in official sources indicate that a percentage of women reported an observable improvement or a complete absence of hot flashes following a course of treatment. The reported effects were noted to increase over a three-month period in some analyses.

Q: Is the onset of action different for everyone?

A: The official guidelines provide a typical course of treatment initiated for five to ten days until symptoms subside. While this offers a general expectation, individual responses and the exact timing of symptom relief may vary from person to person.

Q: Can Ци-Клим Аланин be used before starting menopause?

A: The official indications describe the medicine as intended for use during the climacteric period. The climacteric period is a time of transition that typically encompasses the years leading up to menopause (perimenopause), as well as the time after.

Q: Does the evidence for Ци-Клим Аланин come from randomized controlled trials?

A: The clinical evidence supporting the use of this product comes from formal clinical trial analyses and summaries used for regulatory approval. These studies involve structured comparisons and safety analyses, often including randomized groups, to evaluate the product's profile.

Q: Do I need to stop taking it when my hot flashes stop?

A: Official regulatory guidance describes that treatment is typically continued until the vasomotor symptoms subside. If symptoms recur later, the official documents describe the allowance for a further cycle of administration to be commenced.

Q: Are there any warnings about liver function and Ци-Клим Аланин?

A: Official adverse reaction summaries and contraindications do not list specific warnings related to liver function. It is noted in some regulatory documents, however, that severe renal impairment is a restriction for use.

Q: Does taking more than the suggested amount increase the effects?

A: The official documentation specifies a maximum daily dose. The consequences of exceeding this dose are generally not addressed in terms of increased efficacy, and doing so moves outside the scope of documented use.

Q: Are there different versions or strengths of Ци-Клим Аланин?

A: The official composition summaries describe the product as a single-component tablet containing 400 mg of beta-alanine per tablet. Different versions or strengths are not specified in the official composition and form summary.

Q: What does 'contraindication' mean in relation to this drug?

A: According to official medical terminology, a contraindication is a condition or circumstance that makes a particular treatment potentially harmful or inappropriate. For this medicine, the listed contraindications include pregnancy, lactation, and known hypersensitivity to any component.

Q: Does it help with mood changes or irritability?

A: The medicine is specifically indicated for physical vasomotor symptoms and is not intended for the treatment of mood changes or irritability. Clinical research focuses primarily on physical symptoms and secondary effects on quality of life and sleep.

Q: Does taking Ци-Клим Аланин cause any change in laboratory test results?

A: Official adverse reaction summaries do not list changes in common laboratory test results among the expected side effects. Clinical trials involving the active ingredient typically measure common clinical blood parameters in study participants.

Q: Do any official sources mention how to handle a missed dose?

A: Official regulatory documents focus on establishing the recommended daily dose, dosage adjustments, and treatment duration. Specific instructions on how to handle a missed dose are generally not provided in the official posology and method of administration section.

Q: Can people who are lactose intolerant take Ци-Клим Аланин?

A: Official regulatory documents detail the product's composition, including the active ingredient and standard inert solid excipients. Information regarding specific allergens like lactose or gluten is contained within the full list of excipients in the product documentation.

How to Store and Dispose of Ци-Клим Аланин

The storage and disposal of beta-Alanine tablets (Ци-Клим Аланин) are defined by specific regulatory requirements to maintain product stability and ensure household safety.

Official Storage Requirements

Storage Condition	Requirement
Temperature	Store at a temperature not exceeding 25, C
Child Safety	Keep out of the sight and reach of children
Shelf Life	The product has a maximum shelf life of 3 years

Handling and Disposal Instructions

To ensure proper stability, the medicinal product must be protected from excessive heat and must not be stored above 25, C. Use of the product is strictly forbidden once the 3-year expiration date indicated on the package has been reached. No specific instructions for environmental or hazardous waste disposal are provided in the official documentation.